MX2013011532A - Inhibidores de la proteina 90 de choque termico (hsp90). - Google Patents

Inhibidores de la proteina 90 de choque termico (hsp90).

Info

Publication number
MX2013011532A
MX2013011532A MX2013011532A MX2013011532A MX2013011532A MX 2013011532 A MX2013011532 A MX 2013011532A MX 2013011532 A MX2013011532 A MX 2013011532A MX 2013011532 A MX2013011532 A MX 2013011532A MX 2013011532 A MX2013011532 A MX 2013011532A
Authority
MX
Mexico
Prior art keywords
compounds
formulae
compound
formula
effective amount
Prior art date
Application number
MX2013011532A
Other languages
English (en)
Other versions
MX360390B (es
Inventor
Weilin Sun
Tony Taldone
Pallav Patel
Gabriela Chiosis
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of MX2013011532A publication Critical patent/MX2013011532A/es
Publication of MX360390B publication Critical patent/MX360390B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La descripción se refiere a compuestos de las fórmulas (lA) y (IB) y slaes farmacéuticamente aceptables de los mismos, en donde Z1, Z2, Z3, Xa, Xb, Xc, Xd, Y, X2 y X4, son como se definen en la presente, a composiciones que comprenden una cantidad efectiva de un compuesto de la fórmula (IA) y/o (IB), y a métodos para tratar y prevenir una condición, este cancer que sobreexpresa Her-cinasas, que comprende administrar a un paciente en necesidad de lo mismo una cantidad terapéuticamente efectiva de un compuesto de la fórmula (lA) y/o (IB). La descripción se refiere adicionalmente a compuestos de las Fórmulas (lA) y/o (IB) en los cuales X2 es un grupo saliente para intrudicir un átomo radiomarcado, tal como 124I o 131I y a métodos para usar estos compuestos en la preparación de compuestos radiomarcados, particularmente para el uso en formación de imágenes.
MX2013011532A 2011-04-05 2012-04-05 Inhibidores de la proteina 90 de choque termico (hsp90). MX360390B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472061P 2011-04-05 2011-04-05
PCT/US2012/032371 WO2012138894A1 (en) 2011-04-05 2012-04-05 Hsp90 inhibitors

Publications (2)

Publication Number Publication Date
MX2013011532A true MX2013011532A (es) 2014-08-22
MX360390B MX360390B (es) 2018-10-31

Family

ID=48166734

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011532A MX360390B (es) 2011-04-05 2012-04-05 Inhibidores de la proteina 90 de choque termico (hsp90).

Country Status (11)

Country Link
US (2) US9346808B2 (es)
EP (1) EP2694505B1 (es)
JP (1) JP6266506B2 (es)
KR (1) KR102010222B1 (es)
CN (1) CN103582642B (es)
AU (1) AU2012240077C1 (es)
BR (1) BR112013025634A2 (es)
CA (1) CA2832530C (es)
EA (1) EA201391334A1 (es)
MX (1) MX360390B (es)
WO (1) WO2012138894A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US10336757B2 (en) 2006-06-30 2019-07-02 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
NZ599138A (en) 2009-10-07 2014-06-27 Sloan Kettering Inst Cancer Purine derivatives useful as hsp90 inhibitors
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EP3208615B1 (en) 2011-07-08 2019-10-09 Sloan Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
JP6539275B2 (ja) 2013-08-16 2019-07-03 メモリアル スローン ケタリング キャンサー センター 選択的ｇｒｐ９４阻害剤およびその使用
CA2934850C (en) * 2013-12-23 2022-12-06 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
CN113521314A (zh) * 2014-09-17 2021-10-22 纪念斯隆-凯特琳癌症中心 Hsp90-靶向炎症和感染成像及治疗
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
US20180280397A1 (en) 2015-10-05 2018-10-04 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer
EP3641751A4 (en) * 2017-06-23 2021-03-31 Samus Therapeutics, Inc. EPICHAPEROME INHIBITOR THERAPY OF TRAUMATIC BRAIN INJURY AND ASSOCIATED SEQUELLA

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1023315B1 (en) 1997-05-14 2010-03-10 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
JP2002541255A (ja) 1999-04-09 2002-12-03 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物
KR100850727B1 (ko) 2000-11-02 2008-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90에 결합하기 위한 소분자 조성물
US7067507B2 (en) 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
JP4397691B2 (ja) 2001-10-30 2010-01-13 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
EP1450784A4 (en) 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
CA2477344A1 (en) 2002-02-28 2003-09-04 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents
US7592143B2 (en) 2003-04-18 2009-09-22 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
CN101906106A (zh) 2003-09-18 2010-12-08 康福玛医药公司 作为hsp90-抑制剂的新的杂环化合物
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2007075572A2 (en) 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
WO2007134298A2 (en) * 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
US10336757B2 (en) 2006-06-30 2019-07-02 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
US20080221132A1 (en) 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
FR2906824B1 (fr) 2006-10-09 2008-12-26 Roger Mondelin Sas Soc Par Act Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) * 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
EA019103B1 (ru) 2007-03-20 2014-01-30 Кьюрис, Инк. Конденсированный аминопиридин в качестве ингибиторов hsp90
WO2008115262A2 (en) * 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
WO2009007399A1 (en) * 2007-07-12 2009-01-15 Crystax Pharmaceuticals, S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
NZ586129A (en) * 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
CA3017874A1 (en) 2009-01-16 2010-07-22 Curis, Inc. Fused amino pyridines for the treatment of brain tumors
NZ599138A (en) 2009-10-07 2014-06-27 Sloan Kettering Inst Cancer Purine derivatives useful as hsp90 inhibitors
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
JP6539275B2 (ja) 2013-08-16 2019-07-03 メモリアル スローン ケタリング キャンサー センター 選択的ｇｒｐ９４阻害剤およびその使用

Also Published As

Publication number Publication date
US9346808B2 (en) 2016-05-24
WO2012138894A1 (en) 2012-10-11
KR20140062429A (ko) 2014-05-23
CA2832530C (en) 2021-02-16
US20160264577A1 (en) 2016-09-15
CN103582642A (zh) 2014-02-12
CN103582642B (zh) 2021-05-11
US20140088121A1 (en) 2014-03-27
AU2012240077B2 (en) 2017-04-20
WO2012138894A4 (en) 2012-12-06
NZ616758A (en) 2016-01-29
EP2694505B1 (en) 2022-04-27
EA201391334A1 (ru) 2014-06-30
AU2012240077C1 (en) 2017-08-10
MX360390B (es) 2018-10-31
AU2012240077A1 (en) 2013-10-31
JP6266506B2 (ja) 2018-01-24
US9926321B2 (en) 2018-03-27
BR112013025634A2 (pt) 2016-07-19
EP2694505A1 (en) 2014-02-12
KR102010222B1 (ko) 2019-08-13
JP2014510148A (ja) 2014-04-24
CA2832530A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
MX2013011532A (es) Inhibidores de la proteina 90 de choque termico (hsp90).
NZ603155A (en) Phospholipid drug analogs
EA201391337A1 (ru) Ингибиторы hsp90
MX349159B (es) Derivados deuterados de ivacaftor.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
PH12015500513A1 (en) Methods for the treatment of locally advanced breast cancer
WO2010132999A8 (en) Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
PH12016500164A1 (en) Therapeutically active compounds and their methods of use
MX2013012588A (es) Inhibidores de cinasa.
NZ726366A (en) Syk inhibitors
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
BR112013022801A2 (pt) combinações de terapia para malignidades hematológicas
WO2012078757A3 (en) Combination for breast cancer therapy with hsp90 inhibitory compounds
MX2014008021A (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
WO2009127669A3 (en) Ido inhibitors and therapeutic uses thereof
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
WO2012141796A3 (en) Prostate cancer therapy with hsp90 inhibitory compounds
IN2014DN08886A (es)
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
EA201270347A1 (ru) Производные апогоссиполона в качестве противоопухолевых агентов
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
MX345264B (es) Derivado de azol.
IN2014CN02315A (es)

Legal Events

Date Code Title Description
FG Grant or registration